GHR Foundation
  • Impact Areas
    • Global Engagement >
      • Children in Families
      • Prepare The Future
      • Programs in Transition >
        • BridgeBuilder >
          • Overview
          • 2017 Top Ideas >
            • Peace Direct
            • BioCarbon Engineering
            • LIFT Chicago
            • Local Youth Corner Cameroon
            • NaTakallam
          • 2018 Top Ideas >
            • This is My Backyard
            • Found in Translation
            • Producers Direct
            • War Child Canada
            • My Choices Foundation
          • 2019 Top Ideas >
            • Top Manta
            • Five One Labs
            • SAMA for All
            • Talent Beyond Boundaries
            • FaithAction
        • Inter-Religious Action
        • Sister Support
    • Catholic Education
    • Twin Cities Racial Equity (TCRE)
    • Alzheimer's Initiative
  • News
  • About Us
    • The Foundation
    • History & Legacy
    • Team >
      • Staff
      • Committees
      • Board
    • FAQs
    • Grants & Financials
  • Contact

Washington Post: Is it Alzheimer’s? Families want to know, and blood tests may offer answers.

12/1/2022

0 Comments

 
Picture
(Laura Padilla Castellanos/The Washington Post)
Excitement and anticipation are building for the use of blood tests to detect Alzheimer’s Disease. A recent article in the Washington Post detailed the work of GHR partner C2N Diagnostics and the groundbreaking research of its co-founder, Dr. Randall Bateman.

From The Washington Post:

“For C2N, the journey to this moment began years ago. It started, like many advances in science, with a few seemingly simple questions that Bateman, then a postdoctoral research fellow, asked Holtzman, his mentor. Why do people — but not other mammals — get amyloid plaques in their brains? Is the protein accumulating and not being cleared? In 2004, Bateman launched a groundbreaking experiment to measure how quickly amyloid is produced and cleared by the brain. For 36 hours, spinal catheters collected cerebrospinal fluid from several participants, some of whom had Alzheimer’s. Bateman served as his own first subject. The study showed that Alzheimer’s patients produced amyloid beta at the same rate as other people but cleared it more slowly. Bateman theorized that the clearance rates might form the basis for a diagnostic test, but ultimately went in a different direction. Brain abnormalities develop 10 to 20 years before symptoms emerge, suggesting people might be able to take steps to delay or prevent the disease. Blood tests could alert individuals to their risks, allowing them to receive a preventive therapy, if one is developed, or pursue better exercise and diet.”

Read more on the the Alzheimer's blood test research landscape.

GHR’s goal is to help patients and families live full lives in a world where Alzheimer’s Disease becomes a preventable condition. GHR aims to halt Alzheimer's disease prior to the onset of cognitive symptoms by supporting new diagnostic tools and prevention trials. Learn more about our work on Alzheimer’s prevention.

0 Comments



Leave a Reply.

    Categories

    All
    A4
    Africa
    Alzheimer's
    Alzheimer's Association
    Annual Report
    BridgeBuilder
    C2N
    Cambodia
    Catholic Schools
    Central African Republic
    Children In Families
    Coverage
    COVID 19
    COVID-19
    Design Build
    Develop Diagnostics
    DIAN
    DIAN Primary Prevention
    DIAN TU
    DIAN-TU
    Education
    Faith & Development
    Global
    Global Development
    Health
    Higher Education
    Inter-Religious Action
    Kenya
    La Jolla Institute
    Legacy
    Mayo Clinic
    Mayo Clinic Study Of Aging
    Myanmar
    Nepal
    Nigeria
    NIH NIA
    NIH-NIA
    Observational Studies
    Podcast
    PrecivityAD
    Prevention Trials
    Sister Support
    Solutions
    Twin Cities Racial Equity
    Uganda
    U.S.
    Work Of The Church
    Zambia

    Archives

    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    October 2019
    September 2019
    August 2019
    July 2019
    May 2019
    April 2019
    March 2019
    December 2018
    November 2018
    October 2018
    September 2018
    June 2018
    May 2018
    April 2018
    February 2018
    January 2018
    November 2017
    October 2017
    August 2017
    July 2017
    May 2017
    April 2017
    March 2017
    January 2017
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    August 2014
    July 2014
    May 2014
    April 2014
    March 2014
    October 2013
    December 2012

    RSS Feed

CONNECT WITH US

IMPACT AREAS  |  NEWS  |  ABOUT  |  JOBS  | ​ CONTACT  
Privacy Policy  |  Terms of Use
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2022 GHR FOUNDATION
All Rights Reserved.